Genetics and origin of antiphospholipid syndrome

Antiphospholipid Antibody Syndrome: From Bench to Bedside

Volumn , Issue , 2015, Pages 1-12

  Soriano, Alessandra ^a,b   Blank, Miri ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944592955     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-11044-8_1     Document Type: Chapter

References (62)

1. Meroni PL, Borghi MO, Raschi E et al (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7:330-339
2. McNeil HP, Simpson RJ, Cherterman CN et al (1990) Antiphospholipid antibodies are directed against a complex antigen that includes lipid binding inhibitor of coagulation: β2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87:4120-4124
3. Galli M, Comfurius P, Maassen C et al (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544-1547
4. Amengual O, Atsumi T, Koike T (2004) Antiprothrombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immunol 112:144-149
5. Mackworth-Young C, Chan J, Harris N (1987) High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheumatol 14:723-726
6. Matthey F, Walshe K, Mackie IJ et al (1989) Familial occurrence of the antiphospholipid syndrome. J Clin Pathol 42:495-497
7. Ilyas Kamboh M, Wang X, Kao HA et al (2013) Genome wide association study for antiphospholipid antibodies. Autoimmune Dis 2013:761046
8. Willis R, Nigel Harris E, Pierangeli SS (2012) Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 38:305-321
9. Castro-Marrero J, Balada E, Vilardell-Tarr�s M et al (2009) Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br J Haematol 147:289-296
10. Gharavi AE, Pierangeli SS, Harris EN (2001) Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 27:551-563
11. Gharavi AE, Pierangeli SS, Harris EN (2003) Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology 207:37-42
12. Harvey AM, Shulman LE (1966) Connective tissue disease and the chronic biologic falsepositive test for syphilis (BFP reaction). Med Clin North Am 50:1271-1279
13. Exner T, Barber S, Kronenberg H et al (1980) Familial association of the lupus anticoagulant. Br J Haematol 45:89-96
14. Jolidon RM, Knecht H, Humair L et al (1991) Different clinical presentations of a lupus anticoagulant in the same family. Klin Wochenschr 69:340-344
15. Rouget JP, Goudemand J, Montreuil G et al (1982) Lupus anticoagulant: a familial observation. Lancet 2(8289):105
16. Mackie IJ, Colaco CB, Machin SJ (1987) Familial lupus anticoagulants. Br J Haematol 67:359-363
17. Goel N, Ortel TL, Bali D et al (1999) Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum 42:318-327
18. Caliz R, Atsumi T, Kondeatis E et al (2001) HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford) 40:31-36
19. Bertolaccini ML, Atsumi T, Caliz AR et al (2000) Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 43:683-688
20. Vargas-Alarcon G, Granados J, Bekker C et al (1995) Association of HLA-DR5 (possibly DRB11201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum 38:1340-1341
21. Galeazzi M, Sebastiani GD, Tincani A et al (2000) HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 9:47-55
22. Arnett FC, Thiagarajan P, Ahn C et al (1999) Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 42:268-274
23. Reverter JC, Tassies MD (2009) Genetic aspects of the antiphospholipid syndrome: associations with clinical manifestations. In: Handbook of systemic autoimmune diseases. Antiphospholipid syndrome in systemic autoimmune diseases. (Ed. by R. Cervera, J.C. Reverter and M. Khamashta). 10:91-103.
24. Sch�tt M, Kl�ter H, Hagedorn-Greiwe M et al (1998) Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus 7:176-182
25. Brenner B, Vulfsons SL, Lanir N et al (1996) Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 94:166-167
26. Chopra N, Koren S, Greer WL et al (2002) Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 29:1683-1688
27. Ames PR, Margaglione M, Tommasino C et al (2001) Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 12:699-704
28. Lincz LF, Adams MJ, Scorgie FE et al (2007) Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagul Fibrinolysis 18:559-564
29. Yasuda S, Tsutsumi A, Atsumi T et al (2002) Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 29:1192-1197
30. de Laat B, Derksen RH, Mackie IJ et al (2006) Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 65:1468-1472
31. Bugert P, Pabinger I, Stamer K et al (2007) The risk of thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. Thromb Haemost 97:573-580
32. Pierangeli SS, Vega-Ostertag ME, Raschi E et al (2007) Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 66:1327-1333
33. Hang LM, Izui S, Dixon FJ (1981) (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 154:216-221
34. Oyaizu N, Yasumizu R, Miyama-Inaba M et al (1988) (NZW x BXSB) F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med 167:2017-2022
35. Papalardo E, Romay-Penabad Z, Christadoss P et al (2010) Induction of pathogenic antiphospholipid antibodies in vivo are dependent on expression of MCH-II genes. Lupus 19:496
36. Hashimoto Y, Kawamura M, Ichikawa K et al (1992) Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 149:1063-1068
37. Gharavi AE, Sammaritano LR, Wen J et al (1992) Induction of antiphospholipid antibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 90:1105-1109
38. Wasserman A (1907) �ber Entwicklung und den Gegenwartingen Stand der Serodiagnostic gegen�ber Syphilis. Berl Klin Wochenschr 44:1599-1634
39. Harris EN, Gharavi AE, Boey ML et al (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211-1214
40. Levy Y, Almog O, Gorshtein A et al (2006) The environment and antiphospholipid syndrome. Lupus 15:784-790
41. Gharavi EE, Chaimovich H, Cucurull E et al (1999) Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 8:449-455
42. Gharavi AE, Pierangeli SS, Espinola RG et al (2002) Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 46:545-552
43. Gharavi AE, Vega-Ostertag M, Espinola RG et al (2004) Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus 13:17-23
44. Blank M, Shoenfeld Y, Cabilly S et al (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci 96:5164-5168
45. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y (2002) Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109:797-804
46. Pierangeli SS, Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, Roye-Green K, Harris EN, Shoenfeld Y (2004) A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun 22: 217-225
47. Meroni PL, Raschi E, Testoni C, Parisio A, Borghi MO (2004) Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 3:510-515
48. Benson MJ, Elgueta R, Schpero W et al (2009) Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med 206:2013-2025
49. Khoruts A, Mondino A, Pape KA et al (1998) A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 187:225-236
50. Piroux V, Eschwege V, Freyssinet JM (1997) Cell damage at the origin of antiphospholipid antibodies and their pathogenic potential in recurrent pregnancy loss. Infect Dis Obstet Gynecol 5:176-180
51. Levine JS, Koh JS, Subang R et al (1999) Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp Mol Pathol 66:82-98
52. Blank M, Israeli E, Shoenfeld Y (2012) When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants. Lupus 21:711-714
53. Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME (2009) Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 60:2468-2471
54. Fredi M, Tincani A, Yin H, Delgado-Vega AM, Borghi MO, Meroni PL, Alarcon-Riquelme ME (2010) IRF5 is associated with antiphospholipid syndrome but is not a major risk factor. Arthritis Rheum 62:1201-1202
55. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni PL, Tedesco F (2005) Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:2340-2346
56. Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, Bulla R, Grossi C, Borghi MO, Meroni PL, Tedesco F (2011) In vivo distribution of β2-glycoprotein I under various pathophysiologic conditions. Blood 118:4231-4238
57. Agostinis C, Durigutto P, Sblattero D, Borghi MO, Grossi C, Giuda F, Bulla R, Macor P, Pregnolato F, Meroni PL, Tedesco F (2014) A non-complement fixing antibody to β2-glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123:3478-3487
58. Raschi E, Chighizola C, Grossi C, Ronda N, Gatti R, Meroni PL, Borghi MO (2014) β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun Mar 27 [Epub ahead of print]
59. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL (2006) Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65:2-6
60. de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF, Maas C (2011) Immune responses against domain I of β2-glycoprotein I are driven by conformational changes. Arthritis Rheum 63:3960-3968
61. Nilsson M, Wasylik S, Morgelin M, Olin AI, Meijers JC, Derksen RH, de Groot PG, Herwald H (2008) The antibacterial activity of peptides derived from human β2-glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 67:482-492
62. van Os GM, Meijers JC, Agar C, Seron MV, Marquart JA, Akesson P, Urbanus RT, Derksen RH, Herwald H, Morgelin M, de Groot PG (2011) Induction of anti β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 9:2447-2456